Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series

Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.

Detalles Bibliográficos
Autores principales: Vitkauskaitė, Monika, Vinikovas, Artūras, Miglinas, Marius, Rimševičius, Laurynas, Čerkauskaitė, Agnė, Mačionienė, Ernesta, Ašakienė, Eglė
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922540/
https://www.ncbi.nlm.nih.gov/pubmed/35317070
http://dx.doi.org/10.1002/ccr3.5573
Descripción
Sumario:Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.

Ejemplares similares